Abeona Therapeutics Inc (NASDAQ: ABEO) is 30.57% higher on its value in year-to-date trading and has touched a low of $3.93 and a high of $7.32 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ABEO stock was last observed hovering at around $5.86 in the last trading session, with the day’s loss setting it -4.16%.
Currently trading at $1.70M, the stock is -3.34% and 1.36% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.28 million and changing 1278735% at the moment leaves the stock 3.74% off its SMA200. ABEO registered 7.36% gain for a year compared to 6-month gain of 6.22%. The firm has a 50-day simple moving average (SMA 50) of $5.9 and a 200-day simple moving average (SMA200) of $5.7646.
The stock witnessed a -6.85% loss in the last 1 month and extending the period to 3 months gives it a 19.60%, and is -0.33% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.84% over the week and 2.12% over the month.
Abeona Therapeutics Inc (ABEO) has around 136 employees, a market worth around $305.92M and $0.00M in sales. Fwd P/E is 42.71. Distance from 52-week low is 52.05% and -18.35% from its 52-week high. The company has generated returns on investments over the last 12 months (-78.05%).
The EPS is expected to grow by 66.99% this year
92.0 institutions hold shares in Abeona Therapeutics Inc (ABEO), with institutional investors hold 67.50% of the company’s shares. The shares outstanding are 48.95M, and float is at 45.31M with Short Float at 13.26%. Institutions hold 63.36% of the Float.
Abeona Therapeutics Inc (ABEO) Insider Activity
The most recent transaction is an insider sale by Vazzano Joseph Walter, the company’s Chief Financial Officer. SEC filings show that Vazzano Joseph Walter sold 17,795 shares of the company’s common stock on Jun 06 ’25 at a price of $6.76 per share for a total of $0.12 million. Following the sale, the insider now owns 0.49 million shares.
Abeona Therapeutics Inc disclosed in a document filed with the SEC on Jun 06 ’25 that Seshadri Vishwas (Chief Executive Officer) sold a total of 50,676 shares of the company’s common stock. The trade occurred on Jun 06 ’25 and was made at $6.76 per share for $0.34 million. Following the transaction, the insider now directly holds 1.3 million shares of the ABEO stock.
Still, SEC filings show that on Jun 06 ’25, O’Malley Brendan M. (SVP, General Counsel) disposed off 10,470 shares at an average price of $6.76 for $70777.0. The insider now directly holds 378,245 shares of Abeona Therapeutics Inc (ABEO).
